Contribution of the Dynamic Intestinal Absorption Model (Diamod) to the Development of a Patient-Centric Drug Formulation

Contribution of the Dynamic Intestinal Absorption Model (Diamod) to the Development of a Patient-Centric Drug Formulation

Authors: Moens F, Larsson A, De Blaiser A, Vandevijver G, Spreafico F, Nicolas JM, Lacombe L, Segregur D, Flanagan T, Berben P
Publication: Mol Pharm
Keywords: biopharmaceutics, formulation assessment, gastroplus, in vitro dissolution, mechanistic absorption, pbbm, PBPK modeling, physiologically based biopharmaceutics
Software: GastroPlus®

Compound X is a weak basic drug targeting the early stages of Parkinson’s disease, for which a theoretical risk assessment has indicated that elevated gastric pH conditions could potentially result in reduced plasma concentrations.

Mechanistic Representation of NAG Release in Relation to Renal Proximal Tubular Cellular Injury

Mechanistic Representation of NAG Release in Relation to Renal Proximal Tubular Cellular Injury

Authors: Hamzavi N, Bhargava P, Stahl SH, Howell BA, Woodhead JL
Conference: American Society of Nephrology (ASN) Kidney Week
Keywords: Acute kidney injury (AKI), cisplatin, CsA, Kidney Week, N-acetyl-beta-D-glucosaminidase, NAG, Quantitative Systems Toxicology (QST), renal injury, RENAsym
Software: RENAsym®
Division: Quantitative Systems Pharmacology (QSP)

Novel Acute kidney injury (AKI) biomarkers enhance disease understanding and aid...

Comparison of Monoclonal Antibody Disposition Predictions Using Different Physiologically Based Pharmacokinetic Modelling Platforms

Comparison of Monoclonal Antibody Disposition Predictions Using Different Physiologically Based Pharmacokinetic Modelling Platforms

Authors: De Sutter PJ, Gasthuys E, Vermeulen A
Publication: J Pharmacokinet Pharmacodyn
Keywords: biologics, gastroplus, Injectables, injections, large molecules, NAMVantage, PBPK modeling, physiologically based pharmacokinetics, tissue concentrations, translational pk
Software: GastroPlus®

Physiologically based pharmacokinetic (PBPK) models can be used to leverage physiological and in vitro data to predict monoclonal antibody (mAb) concentrations in serum and tissues.

Use of In silico Methodologies to Predict the Bioavailability of Oral Suspensions: A Regulatory Approach

Use of In silico Methodologies to Predict the Bioavailability of Oral Suspensions: A Regulatory Approach

Authors: Honório TDS, Simon A, Machado RMC, Rodrigues CR, do Carmo FA, Cabral LM, de Sousa VP
Publication: Curr Pharm Des
Keywords: ACAT, dissolution specifications, gastroplus, IVIVC, mechanistic absorption, pbbm, PBPK modeling, physiologically based biopharmaceutics
Software: GastroPlus®

Oral suspensions are heterogeneous disperse systems, and the particle size distribution, crystalline form of the dispersed solid, and composition of the formulation can be listed as parameters that control the drug dissolution rate and its bioavailability.

Voices in Molecular Pharmaceutics: Meet Dr. Bart Hens, A Sociable Scientist Focusing on Multidisciplinary Connections to Unravel the Gaps of Oral Drug Behavior in the Human Gastrointestinal Tract

Voices in Molecular Pharmaceutics: Meet Dr. Bart Hens, A Sociable Scientist Focusing on Multidisciplinary Connections to Unravel the Gaps of Oral Drug Behavior in the Human Gastrointestinal Tract

Authors: Hens B
Publication: Mol Pharm
Keywords: biopharmaceutics, gastroplus, pbbm, PBPK modeling, physiologically based pharmacokinetics
Software: GastroPlus®

Bart Hens (Pharm.D., Ph.D.) holds a Ph.D. degree in Pharmaceutical Sciences obtained from KU Leuven (Supervisor: Prof. Dr. Patrick Augustijns - Leuven, Belgium).

Repurposing of Strychnine as the Potential Inhibitors of Aldo–keto Reductase Family 1 Members B1 and B10: Computational Modeling and Pharmacokinetic Analysis

Repurposing of Strychnine as the Potential Inhibitors of Aldo–keto Reductase Family 1 Members B1 and B10: Computational Modeling and Pharmacokinetic Analysis

Authors: Sarfraz M, Aziz M, Afzal S, Channar PA, Alsfouk BA, Kandhro GA, Hassan S, Sultan A, Hamad A, Arafat M, Qaiser MN, Ahmed A, Siddiqui F, Ejaz SA
Publication: Protein J
Keywords: admet predictor, gastroplus, high throughput pharmacokinetics, HTPK, PBPK modeling, physiologically based pharmacokinetics
Software: ADMET Predictor®, GastroPlus®

AKR1B1 and AKR1B10 are important members of aldo–keto reductase family which plays a significant role in cancer progression by modulating cellular metabolism.

Adult and pediatric physiologically-based biopharmaceutics modeling to explain lamotrigine immediate release absorption process

Adult and pediatric physiologically-based biopharmaceutics modeling to explain lamotrigine immediate release absorption process

Authors: Caleffi-Marchesini ER, Herling AA, Macente J, Bonan RH, de Freitas Lima P, Moreno R, Alexandre V, Charbe NB, Borghi-Pangoni FB, Cristofoletti R, Diniz A
Publication: CPT Pharmacometrics Syst Pharmacol
Keywords: ACAT, biopharmaceutics, dissolution specifications, formulation design, gastroplus, pbbm, PBPK modeling, pediatrics, physiologically based pharmacokinetics
Software: GastroPlus®

Physiologically-based biopharmaceutics modeling (PBBM) has potential to accelerate the development of new drug and formulations.

The QST modeling approach leveraging known physiology and available clinical data paves the path towards predictions of DILI in pediatrics

The QST modeling approach leveraging known physiology and available clinical data paves the path towards predictions of DILI in pediatrics

Authors: Do Dela A, Yang K, Beaudoin J, Woodhead JL
Conference: AAPS
Keywords: AAPS2023, DILI, DILIsym, drug induced liver injury (DILI), pediatrics, QST modeling, Quantitative Systems Toxicology (QST)
Software: DILIsym®
Division: Quantitative Systems Pharmacology (QSP)

Drug-induced liver injury (DILI) is an underrecognized cause of pediatric liver disease which accounts for almost...